Evidence map›Paper›PMID 28065804›Full record

ArticleInfection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases2017

Limited naturally occurring escape in broadly neutralizing antibody epitopes in hepatitis C glycoprotein E2 and constrained sequence usage in acute infection.

Chaturaka Rodrigo, Melanie R Walker, Preston Leung, Auda A Eltahla, Jason Grebely, Gregory J Dore, Tanya Applegate, Kimberly Page, Sunita Dwivedi, Julie Bruneau and 14 more

Open access · greenAbstract read
In one paragraph

Article in Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 8 institutions in 4 countries.

Chaturaka RodrigoSchool of Medical Sciences, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia. Electronic address: c.rodrigo@unsw.edu.au.
Melanie R WalkerSchool of Medical Sciences, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.
Preston LeungSchool of Medical Sciences, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.
Auda A EltahlaSchool of Medical Sciences, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.
Jason GrebelyThe Kirby Institute, University of New South Wales, Sydney, NSW, Australia.
Gregory J DoreThe Kirby Institute, University of New South Wales, Sydney, NSW, Australia.
Tanya ApplegateThe Kirby Institute, University of New South Wales, Sydney, NSW, Australia.
Kimberly PageDepartment of Epidemiology and Biostatistics, University of New Mexico, Albuquerque, NM, USA.
Sunita DwivediDepartment of Epidemiology and Biostatistics, University of New Mexico, Albuquerque, NM, USA.
Julie BruneauCRCHUM, Université de Montréal, Montreal, QC, Canada.
Meghan D MorrisDepartment of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA.
Andrea L CoxDepartment of Medicine, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
William OsburnDepartment of Medicine, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Arthur Y KimHarvard Medical School, Boston, MA, USA.
Janke SchinkelDepartment of Internal Medicine, Division of Infectious Diseases, Tropical Medicine and AIDS, Center for Infection and Immunity Amsterdam, Academic Medical Center, Meibergdreef, Amsterdam, The Netherlands.
Naglaa H ShoukryCRCHUM, Université de Montréal, Montreal, QC, Canada.
Georg M LauerHarvard Medical School, Boston, MA, USA.
Lisa MaherThe Kirby Institute, University of New South Wales, Sydney, NSW, Australia.
Margaret HellardBurnet Institute, Melbourne, VIC, Australia; Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia.
Maria PrinsDepartment of Internal Medicine, Division of Infectious Diseases, Tropical Medicine and AIDS, Center for Infection and Immunity Amsterdam, Academic Medical Center, Meibergdreef, Amsterdam, The Netherlands; GGD Public Health Service of Amsterdam, Amsterdam, The Netherlands.
Fabio LucianiSchool of Medical Sciences, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.
Andrew R LloydSchool of Medical Sciences, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia; The Kirby Institute, University of New South Wales, Sydney, NSW, Australia.
Rowena A BullSchool of Medical Sciences, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.
InC(3) Study Group
UNSW Sydney · AUAmsterdam UMC Location University of Amsterdam · NLHarvard University · USJohns Hopkins University · USUniversité de Montréal · CAUniversity of New Mexico · USBurnet Institute · AUUniversity of California, San Francisco · US

Funding

Acute Hepatitis C Infection in Young InjectorsR01DA016017 · NIDA · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI PAGE, KIMBERLY · 2002 to 2018
$14.0M
The role of NK cells during acute HCV infection and antiviral therapyU19AI066345 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI KIM, ARTHUR Y · 2005 to 2014
$8.5M
Scientific CoreU19AI088791 · NIAID · JOHNS HOPKINS UNIVERSITY · PI COX, ANDREA L · 2010 to 2020
$8.2M
Treatment of recently acquired hepatitis C virus infectionR01DA015999 · NIDA · UNIVERSITY OF NEW SOUTH WALES · PI DORE, GREGORY JOHN · 2003 to 2014
$3.7M
International Collaborative of prospective studies of HIV and Hepatitis in IDUR01DA031056 · NIDA · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI PAGE, KIMBERLY · 2011 to 2015
$2.2M
Immune Control and Evadion during Acute HCV InfectionU01AI131314 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI LAUER, GEORG MICHAEL · 2016 to 2020
$1.4M
Understanding the interpersonal context of HIV/HCV risk within injecting dyadsK01DA037802 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MORRIS, MEGHAN D · 2014 to 2018
$913k
CIHR MOP-103138CIHR MOP-133680NIAID NIH HHS U01 AI131314NIAID NIH HHS U19 AI066345NIAID NIH HHS U19 AI088791NIDA NIH HHS K01 DA037802NIDA NIH HHS R01 DA015999NIDA NIH HHS R01 DA016017NIDA NIH HHS R01 DA031056
6 · The paper itself

Abstract

Broadly neutralizing antibodies have been associated with spontaneous clearance of the hepatitis C infection as well as viral persistence by immune escape. Further study of neutralizing antibody epitopes is needed to unravel pathways of resistance to virus neutralization, and to identify conserved regions for vaccine design. All reported broadly neutralizing antibody (BNAb) epitopes in the HCV Envelope (E2) glycoprotein were identified. The critical contact residues of these epitopes were mapped onto the linear E2 sequence. All publicly available E2 sequences were then downloaded and the contact residues within the BNAb epitopes were assessed for the level of conservation, as well as the frequency of occurrence of experimentally-proven resistance mutations. Epitopes were also compared between two sequence datasets obtained from samples collected at well-defined time points from acute (<180days) and chronic (>180days) infections, to identify any significant differences in residue usage. The contact residues for all BNAbs were contained within 3 linear regions of the E2 protein sequence. An analysis of 1749 full length E2 sequences from public databases showed that only 10 out of 29 experimentally-proven resistance mutations were present at a frequency >5%. Comparison of subtype 1a viral sequences obtained from samples collected during acute or chronic infection revealed significant differences at positions 610 and 655 with changes in residue (p<0.05), and at position 422 (p<0.001) with a significant difference in variability (entropy). The majority of experimentally-described escape variants do not occur frequently in nature. The observed differences between acute and chronically isolated sequences suggest constraints on residue usage early in infection.

Indexed as

Immune EvasionAcute DiseaseAmino Acid SequenceAntibodies, MonoclonalAntibodies, NeutralizingEpitope MappingEpitopesGene ExpressionHepacivirusHepatitis C AntibodiesHepatitis C, ChronicHumansModels, MolecularMutation RateProtein Structure, SecondaryViral Envelope ProteinsAntibodies, MonoclonalAntibodies, NeutralizingEpitopesglycoprotein E2, Hepatitis C virusHepatitis C AntibodiesViral Envelope ProteinsBroadly neutralizing antibodiesEpitopesGlycoprotein E2Hepatitis CInC(3) collaborative

Identifiers

PMID28065804
PMCPMC5330849
OpenAlexW2567980438

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.